2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy
2019
Cost-Effectiveness of Prostate Radiation Therapy in Men with Newly Diagnosed Low Burden Metastatic Prostate Cancer
Lester-Coll N, Ades S, Yu J, Atherly A, Wallace H, Sprague B. Cost-Effectiveness of Prostate Radiation Therapy in Men with Newly Diagnosed Low Burden Metastatic Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s180-s181. DOI: 10.1016/j.ijrobp.2019.06.221.Peer-Reviewed Original ResearchContemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.
Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.Peer-Reviewed Original ResearchProstate cancer incidenceHealth service areasMetastatic prostate cancerMetastatic prostate cancer incidenceMetastatic diseaseCancer incidenceProstate cancerLocalized diseasePopulation-weighted linear regressionMen 70 yearsEnd Results (SEER) databaseHealth Service regionResults databaseIncidence rateHospital careMetastatic incidenceIncidenceDiseaseCancerLate increasePSALinear regressionMenTemporal relationshipSurveillance